Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: A prospective, multicenter, randomized study

Intestinal Research

Volumn 17, Issue 3, 2019, Pages 349-356

  Park, Soo Kyung ^a   Park, Sang Hyun ^a   Eun, Chang Soo ^b   Seo, Geom Seog ^c   Im, Jong Pil ^d   Kim, Tae Oh ^e   Park, Dong Il ^a  

^a School of Medicine   (South Korea)

^b Hanyang University Guri Hospital   (South Korea)

^c Wonkwang University Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

Author keywords

Colitis; Inflammatory bowel disease; Mesalamine; ulcerative

Indexed keywords

EID: 85077991754     PISSN: 15989100     EISSN: 22881956     Source Type: Journal    
DOI: 10.5217/ir.2018.00064     Document Type: Article

References (29)

1. 1. Choi CH, Kim YH, Kim YS, et al. Guidelines for the management of ulcerative colitis. Korean J Gastroenterol 2012;59:118-140.
2. 2. Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res 2017;15:7-37.
3. 3. Wei SC, Chang TA, Chao TH, et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:266-284.
4. 4. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-211.
5. 5. Kao J, Kwok K, Das KM. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. J Clin Gastroenterol 2010;44:531-535.
6. 6. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;4:CD000543.
7. 7. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982; 285:1012.
8. 8. Hibi T, Ueno F, Matsuoka K, Lee T. Guidelines for the management of ulcerative colitis in Japan: developed through integration of evidence and consensus among experts. IBD Res 2010;4:189-239.
9. 9. Mayberry J. The history of 5-ASA compounds and their use in ulcerative colitis: trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis 2013;22:375-377.
10. 10. Iacucci M, de Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol 2010;24:127-133.
11. 11. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-585.
12. 12. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-769.
13. 13. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010;138:1286-1296.
14. 14. Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a doubleblind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-240.
15. 15. Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflamm Bowel Dis 2017;23:822-832.
16. 16. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902.
17. 17. Scaioli E, Scagliarini M, Cardamone C, et al. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol 2015;27:1418-1424.
18. 18. Scaioli E, Digby RJ, Belluzzi A. Different cutoff levels of fecal calprotectin to predict clinical relapse in ulcerative colitis. Inflamm Bowel Dis 2016;22:E26.
19. 19. Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015;21:11246-11259.
20. 20. Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2016;22:1042-1048.
21. 21. García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010;4:144-152.
22. 22. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014;29:485-491.
23. 23. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res 2017;15: 434-445.
24. 24. Hawthorne AB, Stenson R, Gillespie D, et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2012;18: 1885-1893.
25. 25. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-2933.
26. 26. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:191-198.
27. 27. Kruis W, Jonaitis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;33:313-322.
28. 28. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009;30:908-918.
29. 29. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-1884.